Benefits
Scavenges reactive dicarbonyl compounds formed during oxidative stress
When fats are oxidized, the body makes reactive by-products called dicarbonyls, including isolevuglandins, that can stick to proteins and DNA. 2-HOBA, a small molecule found in buckwheat, reacts with these compounds before they bind. This scavenging action is well shown in laboratory studies; human studies confirm the compound is absorbed but have not measured health outcomes.
Well tolerated in short-term studies in healthy adults
Two early studies in healthy volunteers reported that 2-HOBA acetate was well tolerated. One tested single doses up to 825 mg, and another gave 750 mg three times a day for 15 days, with no clinically important changes in vital signs, ECG or routine blood tests. Both were small and short and did not measure any health benefit.
Lower lipid peroxidation markers in animal and laboratory studies
In mouse studies, 2-HOBA lowered markers of fat oxidation and of protein damage from dicarbonyls. Mice on a fatty-liver diet had about 30% lower blood F2-isoprostanes, a marker of lipid peroxidation, and mice prone to artery plaque had fewer oxidized-fat protein adducts in the aorta. These are animal findings and have not been shown in people.
Protects HDL particles from oxidative modification in laboratory studies
HDL ("good cholesterol") particles can be damaged when immune enzymes oxidize them. In test-tube and mouse experiments, 2-HOBA blocked this dicarbonyl-driven modification of HDL proteins and helped the particles keep their normal job of moving cholesterol out of cells. This has been shown only in the laboratory and in mice, not in human trials.
Immune signaling protein changes measured in healthy adults
In two groups of healthy younger and older adults, 15 days of oral 2-HOBA shifted the blood levels of several immune-signaling proteins measured on a research panel. The study was small, used a before-and-after design, and was run by a company developing the ingredient, so what these laboratory changes mean for health is not yet known.
Mechanism of action
Reacts with dicarbonyls before they bind proteins
2-HOBA carries a chemical group that reacts quickly with reactive gamma-ketoaldehydes such as isolevuglandins and with malondialdehyde. By binding these compounds first, it is meant to keep them from forming adducts on proteins and DNA. This is the compound's defining action in laboratory studies.
A compound found in buckwheat seed
2-HOBA, also called salicylamine, occurs naturally in buckwheat seeds. Supplements use a made (synthetic) version, usually as the acetate salt, to supply larger and more consistent amounts than food would provide.
Absorbed quickly and cleared within hours
In human studies, 2-HOBA was absorbed within about 1 to 2 hours and cleared with a half-life of roughly 2 to 3 hours, so it builds up only slightly with repeated dosing. It was also detected in cerebrospinal fluid, showing it can reach beyond the bloodstream.
Clinical trials
Open-label first-in-human study of six ascending single oral doses of 2-HOBA acetate with safety, tolerability and pharmacokinetic measurements. (Pitchford et al. 2019, BMC Pharmacol Toxicol)
18 healthy adult volunteers.
2-HOBA acetate was reported safe and well tolerated at single doses up to 825 mg. Adverse events were mild and judged unlikely to be related, with no clinically important changes in vital signs, ECG or laboratory tests. It was absorbed within 1 to 2 hours and cleared with a half-life of about 2 hours. This was a safety and pharmacokinetic study, not a test of any health benefit.
Double-blind, randomized, placebo-controlled trial of 2-HOBA acetate 500 or 750 mg every 8 hours for 15 days in healthy volunteers. (Pitchford et al. 2020, BMC Pharmacol Toxicol)
Healthy adult volunteers.
Repeated dosing up to 750 mg three times a day for 15 days was reported safe and well tolerated. The compound built up only slightly between doses, did not interfere with cyclooxygenase (the enzyme aspirin blocks), and was detectable in cerebrospinal fluid. The trial measured safety and pharmacokinetics, not clinical outcomes.
Open-label 15-day study measuring blood immune-protein markers with a targeted inflammation panel before and after oral 2-HOBA. (Rathmacher et al. 2023, Inflammation)
Two cohorts of healthy younger and older adults.
After 15 days, 15 immune-signaling proteins changed significantly, including higher CCL19, IL-12 beta, IL-20R alpha and TNF beta and lower TWEAK. The analysis used a before-and-after design with no placebo group reported, measured laboratory markers only, and was run by a company developing 2-HOBA, so the health meaning is unclear.
Randomized, placebo-controlled pilot trial of 2-HOBA 750 mg three times daily started three days before a planned atrial-fibrillation ablation, with 28-day heart-rhythm monitoring. (Yoneda et al. 2025, Circ Arrhythm Electrophysiol)
Adults scheduled for atrial-fibrillation ablation, randomized 1:1 to 2-HOBA or placebo.
Unexpectedly, people taking 2-HOBA had more irregular-heartbeat recurrences in the 28 days after the procedure than those on placebo (odds ratio 3.65, 95% CI 1.31 to 10.16). Blood isolevuglandin levels did not differ between groups, and after the study drug was stopped there was no difference over 12 months. The authors called the result unexpected and its wider meaning unknown.
Controlled animal study of 2-HOBA versus a non-reactive analogue and vehicle in Ldlr-knockout mice fed a high-fat diet. (Tao et al. 2020, Nat Commun)
Ldlr-knockout mice (a model of inherited high cholesterol).
2-HOBA reduced aortic plaque by about 60% compared with the control treatments, without changing blood cholesterol, and lowered oxidized-fat protein adducts in the artery wall. HDL from treated mice worked better at removing cholesterol from cells. These are animal results and have not been reproduced in people.
Controlled study of 2-HOBA in two mouse models of metabolic-associated steatotic liver disease, with protein-adduct measurements in human liver tissue. (Cheung-Flynn et al. 2025, Nutrients)
Male mice in two fatty-liver models; human liver samples used for tissue measurements only.
In the mice, 2-HOBA lowered liver fibrosis scores and liver enzymes and cut a blood lipid-peroxidation marker by about 30%. Human liver tissue from advanced fatty-liver disease showed more dicarbonyl protein adducts than normal liver, but the compound itself was tested only in male mice.